Cargando…

Phase 1, Open-Label, Dose Escalation, Safety, and Pharmacokinetics Study of ME-344 as a Single Agent in Patients With Refractory Solid Tumors

BACKGROUND: The current phase 1, open-label, dose escalation study was conducted to establish the safety, tolerability, pharmacokinetic profile, and preliminary antitumor activity of the novel mitochondrial inhibitor ME-344 in patients with refractory solid tumors. METHODS: Patients with refractory...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bendell, Johanna C, Patel, Manish R, Infante, Jeffrey R, Kurkjian, Carla D, Jones, Suzanne F, Pant, Shubham, Burris, Howard A, Moreno, Ofir, Esquibel, Vanessa, Levin, Wendy, Moore, Kathleen N
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BlackWell Publishing Ltd 2015
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4406150/ https://www.ncbi.nlm.nih.gov/pubmed/25411085 http://dx.doi.org/10.1002/cncr.29155

Ejemplares similares

A first-in-human dose-escalation study of ME-143, a second generation NADH oxidase inhibitor, in patients with advanced solid tumors
por: Pant, Shubham, et al.
Publicado: (2013)

Safety and activity of IT-139, a ruthenium-based compound, in patients with advanced solid tumours: a first-in-human, open-label, dose-escalation phase I study with expansion cohort
por: Burris, Howard A, et al.
Publicado: (2017)

A Phase Ib Dose-Escalation Study of LCL161 Plus Oral Topotecan for Patients With Relapsed/Refractory Small Cell Lung Cancer and Select Gynecologic Malignancies
por: Johnson, Melissa L, et al.
Publicado: (2023)

Phase I, First‐in‐Human, Dose‐Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Vorolanib in Patients with Advanced Solid Tumors
por: Bendell, Johanna C., et al.
Publicado: (2018)

Factors affecting the pharmacokinetics and pharmacodynamics of PEGylated liposomal irinotecan (IHL-305) in patients with advanced solid tumors
por: Wu, Huali, et al.
Publicado: (2015)

Phase 1 study of oral TAS-102 in patients with refractory metastatic colorectal cancer
por: Bendell, Johanna C., et al.
Publicado: (2015)

Erratum to: Phase 1 study of oral TAS-102 in patients with refractory metastatic colorectal cancer
por: Bendell, Johanna C., et al.
Publicado: (2015)

Phase I dose-escalation and pharmacokinetic study of temozolomide (SCH 52365) for refractory or relapsing malignancies
por: Brada, M, et al.
Publicado: (1999)

Voltage-Dependent Anion Channels Influence Cytotoxicity of ME-344, a Therapeutic Isoflavone
por: Zhang, Leilei, et al.
Publicado: (2020)

A novel isoflavone, ME-344, targets the cytoskeleton in acute myeloid leukemia
por: Jeyaraju, Danny V., et al.
Publicado: (2016)

First-in-human study of the safety, pharmacokinetics, and pharmacodynamics of first-in-class fatty acid synthase inhibitor TVB-2640 alone and with a taxane in advanced tumors
por: Falchook, Gerald, et al.
Publicado: (2021)

A phase I dose‐escalation study to assess safety, tolerability, pharmacokinetics, and preliminary efficacy of the dual mTORC1/mTORC2 kinase inhibitor CC‐223 in patients with advanced solid tumors or multiple myeloma
por: Bendell, Johanna C., et al.
Publicado: (2015)

A phase I dose-escalation study of selumetinib in combination with docetaxel or dacarbazine in patients with advanced solid tumors
por: LoRusso, Patricia M., et al.
Publicado: (2017)

A phase I dose-escalation study of Selumetinib in combination with Erlotinib or Temsirolimus in patients with advanced solid tumors
por: Infante, Jeffrey R., et al.
Publicado: (2017)

Erratum to: A phase I dose-escalation study of Selumetinib in combination with Erlotinib or Temsirolimus in patients with advanced solid tumors
por: Infante, Jeffrey R., et al.
Publicado: (2017)

Pharmacokinetics of escalating single‐dose administration of cannabidiol to cats
por: Rozental, Aaron J., et al.
Publicado: (2022)

Phase 1 study of cardiac safety of TAS-102 in patients with advanced solid tumors
por: Bendell, Johanna C., et al.
Publicado: (2016)

Dose-escalating ruxolitinib for refractory hemophagocytic lymphohistiocytosis
por: Song, Yue, et al.
Publicado: (2023)

Are you threatening me? Development and validation of the Conflict Escalation Questionnaire
por: Scheppa-Lahyani, Miriam Nicole, et al.
Publicado: (2023)

Enhancing anti-AML activity of venetoclax by isoflavone ME-344 through suppression of OXPHOS and/or purine biosynthesis
por: Hurrish, Katie H., et al.
Publicado: (2023)

Intermittent dosing of axitinib combined with chemotherapy is supported by (18)FLT-PET in gastrointestinal tumours
por: Hoh, C K, et al.
Publicado: (2014)

A phase 1 dose-escalation and expansion study of binimetinib (MEK162), a potent and selective oral MEK1/2 inhibitor
por: Bendell, Johanna C, et al.
Publicado: (2017)

CD8+ T cell stimulation with pegylated recombinant human IL-10 in the patient with advanced solid tumors - a Phase I study
por: Naing, Aung, et al.
Publicado: (2015)

Zandelisib (ME-401) in Japanese patients with relapsed or refractory indolent non-Hodgkin’s lymphoma: an open-label, multicenter, dose-escalation phase 1 study
por: Goto, Hideki, et al.
Publicado: (2022)

Non-canonical C-terminal variant of MeCP2 R344W exhibits enhanced degradation rate
por: Chai, Yue, et al.
Publicado: (2023)

Evaluation of CYP3A‐mediated drug–drug interactions with romidepsin in patients with advanced cancer
por: Laille, Eric, et al.
Publicado: (2015)

Ustekinumab dose escalation improves clinical responses in refractory Crohn’s disease
por: Haider, Syedreza A., et al.
Publicado: (2020)

Escalation to Barbiturate-Induced Coma for Refractory Seizures after Liver Transplantation
por: Miles, Brittany, et al.
Publicado: (2022)

Safety and pharmacokinetics of polatuzumab vedotin in Japanese patients with relapsed/refractory B-cell non-Hodgkin lymphoma: a phase 1 dose-escalation study
por: Kinoshita, Tomohiro, et al.
Publicado: (2020)

The legacy of the F344 rat as a cancer bioassay model (a retrospective summary of three common F344 rat neoplasms)
por: Maronpot, Robert R., et al.
Publicado: (2016)

Health Tract No. 344: Marriage and Divorce
Publicado: (1868)

Pharmacokinetic Study of Rucaparib in Patients With Advanced Solid Tumors
por: Shapiro, Geoffrey I., et al.
Publicado: (2018)

P526: SAFETY AND EFFICACY UPDATE FROM CLI120-001: A PHASE1B DOSE ESCALATION STUDY IN RELAPSE-REFRACTORY ACUTE MYELOID LEUKEMIA AND HIGH-RISK MYELODYSPLASIA
por: Lech-Marańda, Ewa, et al.
Publicado: (2023)

Source characteristics of evaporation residues and intermediate mass fragments in $Kr$ induced reactions at 26.4 and 34.4 MeV/nucleon
por: Faure-Ramstein, B, et al.
Publicado: (1994)

First-in-human, dose-escalation, phase 1 study of anti-angiopoietin-2 LY3127804 as monotherapy and in combination with ramucirumab in patients with advanced solid tumours
por: Martin-Liberal, Juan, et al.
Publicado: (2020)

Comparing Plasma Exchange to Escalated Methyl Prednisolone in Refractory Multiple Sclerosis Relapses
por: Pfeuffer, Steffen, et al.
Publicado: (2019)

Spatiotemporal Expression and Molecular Characterization of miR-344b and miR-344c in the Developing Mouse Brain
por: Leong, Jia-Wen, et al.
Publicado: (2016)

The half-life of the 344 keV level in $^{105}$Pd
por: Schrader, H, et al.
Publicado: (1970)

The half-life of the 344 KeV level in $ ^{105}Pd$
por: Schrader, H, et al.
Publicado: (1970)

Carcinogenesis by Nitrosohydroxyethylurea and Nitrosomethoxyethylurea in F344 Rats
por: Lijinsky, William, et al.
Publicado: (1988)

Cannot write session to /tmp/vufind_sessions/sess_gn2eaf7oc35ierei5or52keui2